X

Clinical Trials

Contact Us

Neuroendocrine / Carcinoid

URCC 19075 **MBMC ONLY** (Temporarily Closed to Enrollment)

Multi-Center Randomized Controlled Phase II Trial of Exercise to Treat Chemotherapy-Induced Peripheral Neuropathy (CIPN)


A222004 (JIT – If a possible patient is identified, notify CRA asap as it will take time to open trial through NCORP)

A Randomized Phase III Trial of Olanzapine Versus Megestrol Acetate for Cancer-Associated Anorexia


s2104 (JIT – If a possible patient is identified, notify CRA asap as it will take time to open trial through NCORP)

Randomized Phase II Trial of Postoperative Adjuvant Capecitabine and Temozolomide Versus Observation in High-Risk Pancreatic Neuroendocrine Tumors


URCC-21038

Disparities in REsults of Immune Checkpoint Inhibitor Treatment (DiRECT): A Prospective Cohort Study of Cancer Survivors Treated with anti-PD-1/anti-PD-L1 Immunotherapy in a Community Oncology Setting


S2013: I-CHECKIT

Immune Checkpoint Inhibitor Toxicity (I-CHECKIT): A Prospective Observational Study


A021602

Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients with Advanced NEuroendocrine Tumors After Progression on Everolimus (CABINET)


MATCH: EAY131 (NCT02465050)

MATCH: Molecular analysis for therapy choice. Targeted therapy directed by genetic testing in treating patients with advanced refractory solid tumors or lymphoma.